Europese Unie - Deens - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirusinfektioner - antivirale midler til systemisk anvendelse - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot). det bør overvejes at officielle vejledning om hensigtsmæssig brug af antivirale agenter.

Europese Unie - Deens - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - ciclesonide - luftveje, andre lægemidler mod obstruktiv sygdomme, inhalationsmidler - heste - til lindring af kliniske tegn på svær enhovede astma (tidligere kendt som tilbagevendende luftvejsobstruktion – (rao), sommer græs, der er forbundet tilbagevendende luftvejsobstruktion – (spa-rao)).

Denemarken - Deens - SEGES Landbrug & Fødevarer

idverde bomendienst b.v. (tidligere btl bomendienst b.v.) - verticillium - suspensionskoncentrat - 10000000 cfu/ml verticillium albo-atrum strain wcs850

Europese Unie - Deens - EMA (European Medicines Agency)

novartis europharm limited - ruxolitinib (som phosphat) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastiske midler - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi er indiceret til behandling af voksne patienter med polycythaemia vera, som er resistente over for eller intolerante over for hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.

Europese Unie - Deens - EMA (European Medicines Agency)

genzyme europe b.v. - alemtuzumab - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - mabcampath er indiceret til behandling af patienter med b-celle kronisk lymfocytisk leukæmi (bcll), for hvem fludarabinkombinationskemoterapi ikke er passende.

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

boehringer ingelheim int. gmbh - ipratropiumbromidmonohydrat - næsespray, opløsning - 21 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - ipratropiumbromidmonohydrat - næsespray, opløsning - 21 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - ipratropiumbromidmonohydrat - næsespray, opløsning - 21 mikrogram/dosis

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - alanin, arginin, glycin, histidin, isoleucin, leucin, lysinacetat, methionin, phenylalanin, prolin, serin, taurin, threonin, tryptophan, tyrosin, valin - infusionsvæske, emulsion

Denemarken - Deens - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - alanin, arginin, glycin, histidin, isoleucin, leucin, lysinacetat, methionin, phenylalanin, prolin, serin, taurin, threonin, tryptophan, tyrosin, valin - infusionsvæske, emulsion